JNJ JNJ ジョンソン・エンド・ジョンソン

 JNJのチャート


 JNJの企業情報

symbol JNJ
会社名 Johnson_Johnson (JNJ ジョンソン・エンド・ジョンソン)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 ジョンソン・アンド・ジョンソン(Johnson_Johnson)は医療分野において各種製品の研究・開発・製造・販売に従事する持株会社である。同社は消費者、医薬品、医療デバイスという3つの事業区分により構成される。同社は人間の健康と幸福に関連する商品を中心に提供する。消費者事業はベビー・ケア、口腔ケア、スキン・ケア、市販薬、女性の健康と創傷ケア市場に使用される各種製品を含む。医薬品事業は免疫学、感染症、神経科学、腫瘍学、心臓血管と代謝疾患を含む5つの治療分野を中心とする。医療デバイス事業は整形外科、外科手術、心臓血管、糖尿病ケア及び視力ケア分野に使用される製品を含む。研究施設は米国、ベルギー、ブラジルカナダ中国、フランス、ドイツ、インド、イスラエル、日本、オランダ、シンガポール、スイス、英国に位置する。  ジョンソン&ジョンソンは、医療・ヘルスケア製品を提供する米国の持株会社。事業部門は、消費者関連、医薬品、医療機器・診断で構成。目薬、鎮痛剤、胃腸薬などの一般用医薬品や栄養補助食品、抗感染、精神疾患、心循環器などの治療薬を製造、販売する。また、病院で使用される外科手術製品・臨床検査機器・診断薬を扱う。本社はニュ―ジャ―ジ―州。  
本社所在地 One Johnson_Johnson Plaza New Brunswick NJ 08933 USA
代表者氏名 Alex Gorsky
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 732-524-2455
設立年月日 1887年11月
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 135100人
url www.jnj.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 29362.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 372228.90000
売上高 売上高(百万ドル) 81581.00000
企業価値(EV) 企業価値(EV)(百万ドル) 383021.90000
当期純利益 当期純利益(百万ドル) 15297.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 30 December 2018 Johnson_Johnson revenues increased 7% to $81.58B. Net income before extraordinary items increased 7% to $15.3B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income also reflects Interest Income increase of 59% to $611M (income) Restructuring decrease of 19% to $251M (expense).

 JNJのテクニカル分析


 JNJのニュース

   US Hospitalizations Hit New Record As "Mutant" COVID Strain Found In Singapore: Live Updates  2020/12/24 16:34:57 Zero Hedge
US Hospitalizations Hit New Record As "Mutant" COVID Strain Found In Singapore: Live Updates Summary: Singapore confirms first case of UK virus strain US hospitalizations hit new record Brazil study shows China vaccine 50% effective India confirms 24K+ new cases China confirms 17 new cases NY extends eviction moratorium Sydney residents asked to "limit mobility" * * * As we head further into what's already been a busy day before Christmas (a day when markets close early and many Americans take off from work), millions of Americans, and other Christians around the world, are preparing to celebrate a holiday that, for many, will probably be a markedly different holiday than what they're accustomed to. According to Johns Hopkins, global cases have reached 78.6MM, while the worldwide death toll is nearing 1.8MM. In the UK, a Brexit deal has finally been reached, but citizens are seemingly more concerned with the line of lorries at the border and news reports about super-infectious COVID-19 mutations prompt people to doubt or question the efficacy of vaccines ( despite all that trial data ) than about fisheries, especially after Britain reported a record 39K+ new cases the other day.
   All countries in the European Union will launch the immunization campaign on December 27  2020/12/24 13:51:49 Novinite
Each vaccinated Bulgarian citizen will receive a European immunization passport The first 10,000 vaccines developed by Pfizer/Biontech will arrive on December 26 in Bulgaria. On the next day the immunization will begin and the first vaccinated will be medics working on the front line in the fight against COVID 19. This became clear at the briefing of the National Operations Headquarters. All countries in the European Union will launch the immunization campaign on December 27 at the same time. "By the end of January, we expect to have 100,000 doses, which will be enough for 50,000 people," said Bogdan Kirilov, director of the Bulgarian Medicines Agency. The first vaccinated will be the medics on the first line, at least that is the organization in the Military Medical Academy, explained Prof. Gen. Ventsislav Mutafchiiski. "Doctors, nurses and orderlies are included in the lists. The clinics that do not work on the front line are waiting for now," he said, according to the MMA vaccination procedure.
   South Korea secures Covid-19 vaccine deals as new restrictions take effect  2020/12/24 05:07:41 FRANCE 24
South Korea has signed deals with Pfizer Inc and Johnson & Johnson’s Janssen to import coronavirus vaccines to cover up to 16 million people, as it grapples with the third wave of infections, Prime Minister Chung Sye-kyun told a televised briefing on Thursday.
   Point-of-Care Testing Devices Market With Top Players like Danaher Corporation, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Alere, Siemens AG, Quidel Corporation, BD, Johnson and Johnson, EKF Diagnostics, Nova Biomedical  2020/12/24 04:02:18 OpenPR
Point of care testing devices are also called besides testing. Point-of-care testing method permits physicians and medical staff to accurately achieve real-time, accurate, lab-quality diagnostic outcomes within minutes rather than hours like other testing methods. Point of care testing devices
   S Korea to import J&J, Pfizer COVID-19 vaccines for 16 million people  2020/12/24 02:18:52 SABC News
South Korea has signed deals with Pfizer Inc and Johnson & Johnson’s Janssen to import coronavirus vaccines to cover up to 16 million people, as it grapples with the third wave of infections, Prime Minister Chung Sye-kyun told a televised briefing on Thursday. The post S Korea to import J&J, Pfizer COVID-19 vaccines for 16 million people appeared first on SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader. .
   How anticipated COVID-19 vaccines are bulk manufactured under Operation Warp Speed  2020/11/12 16:29:06 CBS News
With $628 million from the U.S. government, Emergent Bio-Solutions in Baltimore is scaling up separate Johnson & Johnson and AstraZeneca COVID-19 vaccines, which are still pending FDA approval.
   J&J CEO Gorsky: COVID-19 vaccine makers aren't fighting each other. It's the virus that's the enemy  2020/11/12 15:54:57 FiercePharma
With COVID-19 vaccines and therapeutics rapidly moving ahead, Johnson & Johnson CEO Alex Gorsky said there's not a competition among drugmakers, but a cooperative, industrywide effort to defeat the pandemic. The best scenario, as outlined by Gorsky during a Detroit Economic Club event? "Four or five or six of these vaccines" available next year.
   J&J files applications for subcutaneous Darzalex in multiple myeloma (NYSE:JNJ)  2020/11/12 12:22:36 Seeking Alpha
Johnson & Johnson (NYSE:JNJ) unit The Janssen Pharmaceutical Companies has submitted marketing applications in the U.S. seeking approval of Darzalex Faspro
   Medical Device Reprocessing Market 2020 COVID-19 Impact, Share, Trend, Segmentation and Forecast to 2027 | Stryker Corporation, Johnson & Johnson, Vanguard, Medline ReNewal, Medtronic  2020/11/12 11:09:10 OpenPR
Market Research Inc has recently announced the addition of a new research report to its expanding repository. The research report, titled “Global Medical Device Reprocessing Market Report” offers a clear understanding of the subject matter. The report has been compiled
   Where Things Stand in the Race for a Covid-19 Vaccine  2020/11/12 09:00:38 The Washington Post
Thousands of researchers in more than 30 countries have been collaborating and competing this year on about 200 projects to develop a vaccine against the novel coronavirus in record time. In the most encouraging scientific advance so far, the vaccine being developed by Pfizer Inc. and BioNTech SE prevented more than 90% of symptomatic infections in a study of tens of thousands of volunteers. However, earlier decisions by AstraZeneca Plc and Johnson & Johnson to pause testing on their promisi

 関連キーワード  (医薬品 米国株 JNJ ジョンソン・エンド・ジョンソン JNJ )

 twitter  (公式ツイッターやCEOツイッターなど)

JNJ動画